New England Journal of Medicine, Volume 394, Issue 16, April 23, 2026: Key Research and Clinical Insights

A new study published in the New England Journal of Medicine reports on the use of evolocumab in patients without a previous myocardial infarction or stroke, showing significant reductions in low-density lipoprotein cholesterol and cardiovascular events in this population.

The research, published in Volume 394, Issue 16 of the journal on April 23, 2026, evaluated evolocumab, a PCSK9 inhibitor, in individuals at risk for atherosclerotic cardiovascular disease but without prior history of heart attack or stroke. The findings indicate that the treatment led to meaningful lowering of LDL cholesterol and a reduction in major adverse cardiovascular events compared to placebo.

According to the study authors, evolocumab demonstrated consistent efficacy in reducing cardiovascular risk among patients who had not previously experienced a myocardial infarction or stroke, supporting its potential role in primary prevention strategies for high-risk individuals.

The results contribute to growing evidence on the use of PCSK9 inhibitors beyond secondary prevention, suggesting possible applications in earlier stages of cardiovascular risk management when lifestyle and statin therapy are insufficient.

As with all medical treatments, the researchers noted that decisions about evolocumab use should be made in consultation with healthcare providers, considering individual risk factors, potential benefits, and any contraindications.